{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:09:05Z","timestamp":1789834145878,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Cardiovascular adverse events (CVAEs) associated with bispecific T\u2010cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014\u2013September 2025), reports listing BsAbs as the primary suspected drug (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097647) were compared with all other drugs in the database (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20097\u2009289\u2009316) and appropriate active comparators. Adjusted reporting odds ratios (aRORs) were estimated using multivariable logistic regression, adjusting for age, sex, cardiovascular comorbidity, disease, and concomitant cardiotoxic medications. Among 7647 BsAb\u2010associated reports (median age: 60 [36\u201371] years; 44.6% female), 1408 (18.4%) involved a CVAE and 447 (5.8%) were fatal. BsAbs showed increased reporting of DIC (aROR: 4.35 [3.18\u20135.96];\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200949), hypotension (1.61 [1.38\u20131.89];\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009181), and fatal CVAEs (1.63 [1.47\u20131.80];\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009447). MM\u2010directed BsAbs were associated with shock (2.09 [1.65\u20132.66]) and myocarditis (3.68 [1.49\u20139.10]). Blinatumomab was associated with DIC (4.41 [3.05\u20136.37]) and hypotension (1.46 [1.18\u20131.81]). Teclistamab showed the strongest myocarditis signal (5.95 [2.16\u201316.43];\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094). Mosunetuzumab showed increased reporting of atrial fibrillation (2.25 [1.15\u20134.38]) and supraventricular tachycardia (2.21 [1.17\u20134.15]). CVAEs occurred earlier than non\u2010CVAEs (median 7 vs. 15\u2009days;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The majority of hypotension (56.4%) and heart failure (44.2%) reports occurred independently of both CRS and infection. Case fatality proportions for shock (60.1%), DIC (51.0%), and heart failure (48.1%) exceeded those for CRS (24.3%). BsAb\u2010associated cardiovascular signals, particularly DIC, hemodynamic events, and fatal CVAEs, varied by agent and target antigen. These findings support the need for cardiovascular\u2010specific monitoring during therapy.\n                  <\/jats:p>","DOI":"10.1002\/ajh.70449","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:02:58Z","timestamp":1784955778000},"page":"2546-2556","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-8677","authenticated-orcid":false,"given":"Malak","family":"Munir","sequence":"first","affiliation":[{"name":"Department of Medicine Rochester General Hospital  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Medicine Rochester General Hospital  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-0404","authenticated-orcid":false,"given":"Dae Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Thalheimer Center for Cardio\u2010Oncology University of Pennsylvania Medicine  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-1427","authenticated-orcid":false,"given":"Sanam","family":"Ghazi","sequence":"additional","affiliation":[{"name":"Cardio\u2010Oncology Program University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-8978","authenticated-orcid":false,"given":"Mustafa M.","family":"Houmsse","sequence":"additional","affiliation":[{"name":"Cardio\u2010Oncology Program University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9876-8703","authenticated-orcid":false,"given":"Saad","family":"Badat","sequence":"additional","affiliation":[{"name":"Cardio\u2010Oncology Program University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Moeed","sequence":"additional","affiliation":[{"name":"Cardio\u2010Oncology Program University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-1174","authenticated-orcid":false,"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine Medical College of Georgia at Augusta University  Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[{"name":"Cardio\u2010Oncology Program University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies Huntsman Cancer Institute, University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010024\u201000905\u2010y"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002528\u20109"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00335\u20107"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_95"},{"key":"e_1_2_11_11_1","unstructured":"National Comprehensive Cancer Network \u201cManagement of CAR T\u2010Cell and Lymphocyte Engager\u2010Related Toxicities Version 2.2026 \u201dNovember 11 2025."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013849"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010025\u201003391\u2010z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102023\u2010008518"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010026\u201001265\u2010z"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.08.044"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15802"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001423\u20107"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15178"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256752"},{"key":"e_1_2_11_21_1","unstructured":"R Core Team \u201cR: A Language and Environment for Statistical Computing \u201d2024 https:\/\/www.R\u2010project.org\/."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e14503"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2026.01.005"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514752"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e19013"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7519"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.07.014"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.038"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70449","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:31Z","timestamp":1788441151000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/ajh.70449"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70449","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"2026-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}